CorMedix Inc. filed its Form 10-Q for the quarterly period ended June 30, 2026 with the U.S. Securities and Exchange Commission on August 13, 2026, reporting net income of $25,988 thousand for the second quarter.

Key Highlights

  • Total revenue and grant income: $101,931 thousand for the three months ended June 30, 2026, up from $39,736 thousand in the same period of 2025.
  • Net income: $25,988 thousand for Q2 2026, compared to $19,828 thousand in Q2 2025.
  • Six-month net income: $64,589 thousand for the six months ended June 30, 2026, versus $40,472 thousand for the same period in 2025.
  • Accumulated deficit reduced: From $176,575 thousand at December 31, 2025, to $111,986 thousand at June 30, 2026.
  • Total assets: $904,052 thousand at June 30, 2026, compared to $826,142 thousand at December 31, 2025.
  • Cash and cash equivalents: $256,692 thousand at June 30, 2026, up from $144,837 thousand at December 31, 2025.
  • Shares outstanding: 77,944,324 common shares as of August 10, 2026.

CorMedix Q2 2026 Financial Results: Revenue Growth and Profitability

According to the filing, CorMedix Inc. (NASDAQ:CRMD) reported total revenue and grant income of $101,931 thousand for the three months ended June 30, 2026, compared to $39,736 thousand for the same quarter in 2025. The Q2 2026 figure comprised product sales, net of $94,341 thousand, contract revenue of $4,966 thousand, and grant income of $2,624 thousand. For the six months ended June 30, 2026, total revenue and grant income reached $229,358 thousand versus $78,818 thousand in the prior-year period.

The company reported income from operations of $42,910 thousand in Q2 2026, compared to $19,544 thousand in Q2 2025. Total operating expenses for the quarter were $34,216 thousand, including research and development of $6,684 thousand, selling and marketing of $12,447 thousand, and general and administrative expenses of $15,085 thousand. Tax expense for the second quarter was $12,745 thousand, up from $522 thousand in Q2 2025. Diluted net income per common share was $0.29 for Q2 2026, versus $0.28 in Q2 2025, based on weighted average diluted shares of 92,479 thousand and 71,919 thousand, respectively.

The condensed consolidated balance sheet showed total stockholders' equity of $460,833 thousand at June 30, 2026, up from $405,307 thousand at December 31, 2025. The company also reported repurchase and retirement of common stock totaling $6,392 thousand during the three months ended June 30, 2026, reducing shares outstanding from 78,395 thousand to 77,667 thousand over that period. Intangible assets, net, stood at $358,472 thousand, and goodwill remained unchanged at $30,002 thousand. Contingent consideration, including both current and long-term portions, totaled $111,619 thousand at June 30, 2026.

What Was Disclosed

CorMedix filed its quarterly report covering the period ended June 30, 2026, disclosing significant year-over-year increases in revenue, net income, and cash, alongside a reduction in accumulated deficit and updates to its balance sheet, including intangible assets and contingent consideration.